Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...

Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in ...

President Donald Trump has found himself in an odd juxtaposition as traditional allies are pushing back on his Most Favored Nation (MFN) plan to reduce the price of prescription drugs.  < | As ...

First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance ...

MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) ...

Joseph Edlow, the director of U.S. Citizenship and Immigration Services, also testified and underscored the administration’s ...

Despite the White House’s claim that the platform offers the world’s lowest prices on prescriptions, Democrats on the House ...

First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided ...

It was way back in September 2025 that President Trump first announced the creation of “TrumpRx”, a direct-to-consumer website that promised heavily-discounted medicines to Americans in need. First ...

MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 202 ...

The TV doctor announced he was leaving his former roles back in October, facing the brunt of the broadcaster's cuts announced last May.